Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke
Completed
Phase 1 Results N/ASummary of Purpose
The primary purpose of the study is to determine whether carbamylated erythropoietin (CEPO) dosed once daily for 5 days is a safe treatment for patients who have suffered an acute ischemic stroke.
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 19 April 2011.
1 May 2009 | 26 Mar 2009 | 1 Dec 2010 | 1 Mar 2011 | 1 Apr 2011 | Unavailable |
Start Date | First Received | 1st Completion | Completion | Verification | Results |
---|
Trial Design
- Allocation: Randomized
- Masking: Double Blind (Subject, Investigator)
- Purpose: Treatment
- Endpoint: Safety Study
- Intervention: Parallel Assignment
Contacts
Not available
View Trial Locations
Recruitment
- Enrollment: 24
- Gender: Both
- Minimum Age: 50 Years
- Accepts Healthy Volunteers: No
- 5 locations, 5 countries
Principal Investigator
- Email contact via H. Lundbeck A/S
LundbeckClinicalTrials@lundbeck.com